UCB enters new drug discovery collaboration with UK partners

UCB has announced a new drug discovery partnership with MRC Technology and the University of Leicester.

The organisations have formed a research consortium that aims to identify new therapeutic opportunities through the innovative use of antibodies in structure-based drug discovery and design.

Antibodies will be used as tools to identify and characterise novel regulatory or allosteric sites on therapeutic target proteins, to stabilise important protein conformational states and to characterise structural features of complexes formed with activity-modulating antibodies.

This knowledge will then be used to guide the discovery and design of novel small molecule therapeutics, allowing unmet clinical needs to be addressed and significant benefits to be delivered for patients.

The research will be based at the University of Leicester and supported by scientists at MRC Technology and UCB's research laboratories.

Neil Weir, senior vice-president of discovery research at UCB, said: "Collaborating with MRC Technology and the University of Leicester to combine our expertise to open up new treatment opportunities through antibody-assisted structure-based drug discovery is a very exciting new venture."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.